SUBSCRIBE
SUBSCRIBE

Capricor Therapeutics

NEWS
Drug Development
Biopharma Update on the Novel Coronavirus: May 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
May 26, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
April 29, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 3
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
April 3, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
stop sign with black board backround
Drug Development
SoCal’s Capricor Places Voluntary Hold on DMD Drug Following Allergic Reaction
Capricor Therapeutics has placed a voluntary hold on its Phase II clinical trial for a Duchene Muscular Dystrophy treatment on hold after a patient experienced a severe allergic reaction during dosing.
December 26, 2018
 · 
3 min read
 · 
Alex Keown
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Business
Capricor Falls as Johnson & Johnson Bails on Stem Cell Heart Med
July 7, 2017
 · 
3 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
SoCal’s Capricor to Reduce Workforce and Shift Focus After Discouraging Trial Results
May 12, 2017
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
June 26, 2026
 · 
7 min read
Press Releases
Capricor Therapeutics to Present at Upcoming Investor Conferences - June 8, 2026
June 8, 2026
 · 
3 min read
Press Releases
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
 · 
13 min read
Press Releases
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
May 4, 2026
 · 
4 min read
Press Releases
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
April 23, 2026
 · 
6 min read
Press Releases
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 13, 2026
 · 
14 min read
Press Releases
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
March 13, 2026
 · 
8 min read
Press Releases
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
March 10, 2026
 · 
6 min read
Press Releases
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
March 9, 2026
 · 
4 min read
Press Releases
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
February 24, 2026
 · 
7 min read
Load More